



αBDNFpro

αmBDNF

Supplementary Fig.1: Uncropped blot referring to Figure 1 a.







#### Supplementary Fig.2: BDNFpro localization in astrocytes

(a) Cortical slices from GFAP-GFP mice fixed 10 min after TBS and processed for immunostaining. z-stack reconstruction shows astrocytes labeled by GFP. Magnification of a ROI shows BDNFpro immunoreactivity and BDNFpro/GFP colocalization signal of one GFP-astrocyte delimited by an approximate territory (white dashed). Scale bars:  $10 \,\mu$ m.

(b) z-stack reconstruction of BDNFpro/GFP colocalization signals in astrocytes from baseline- and TBS-slices from GFAP-GFP mice. Insets show GFP signal. BDNFpro/GFP colocalization was quantified in whole cell using Mander's overlap. \*\*\* p<0.001 (Unpaired t-test); (n = 7 cells, 4 slices, 3 mice for baseline; n = 7 cells, 4 slices, 4 mice for TBS). Scale bars: 10  $\mu$ m.

(c) Stack-by-stack reconstruction of the same astrocytes shown in Fig. 1c. BDNFpro/GFP colocalization in control littermates injected with AAV-GFAP-GFP virus from stack (0,5  $\mu$ m thick) 1, 4, 7, 10, and 13. The last panel shows BDNFpro/GFP colocalization signal. Insets show GFP signal. Scale bars: 10  $\mu$ m.

(d) BDNFpro/GFP colocalization in control littermates injected with AAV-GFAP-GFP was quantified using Pearson's correlation. \*\*\* p<0.001 (Unpaired t-test); (n = 5 cells, 3 slices, 3 mice for baseline; n = 8 cells, 4 slices, 4 mice for TBS).

Data are normalized to baseline and presented as mean  $\pm$  SEM.

b



tamoxifen

p75NTR<sub>deletion/</sub>

breeding

1) loxP-p75<sup>NTR</sup>-loxP mice

### Supplementary Fig. 3: p75-flox mice

(a) Schematic diagram depicting the experimental paradigm. p75-flox mice were generated by crossing (1) loxP-p75<sup>NTR</sup>-loxP mice, expressing flanking exons 4-6 of the p75<sup>NTR</sup> gene with loxP sites; with (2) GLAST-CreER<sup>T2</sup> mice, expressing the inducible version of the Cre recombinase (CreER<sup>T2</sup>) under the control of the GLAST promoter and (3) Rosa-CAGloxP-stop-loxP(LSL)-R26R mice for  $\beta$ -Gal expression. Tamoxifen treatment in p75-flox mice causes the CreER<sup>T2</sup> fusion protein to translocate into the nucleus of GLAST-expressing cells, where it recombines paired loxP sites allowing p75<sup>NTR</sup> gene deletion and  $\beta$ -Gal expression.

(b) Schematic representation of the experimental design. Slices from p75-flox mice and control littermates treated with tamoxifen (-5 to 0) and processed for immunostaining at 14 dptm. z-stack reconstruction of a representative field shows  $\beta$ -Gal staining consistently excluded from NeuN labeled cells. Representative example shows one GFAP-positive astrocyte expressing  $\beta$ -Gal (right). Scale bars: 10 µm.

(c) Schematic representation of the experimental design. Slices from p75-flox mice and control littermates treated with tamoxifen (-5 to 0), injected with AAV-GFAP-GFP adenovirus the last day of tamoxifen treatment (0 dptm) and processed for immunostaining at 3, 7 and 14 dptm. Dot plot depicts the quantification of p75<sup>NTR</sup>/GFP colocalization using Mander's overlap. Data are presented as mean  $\pm$  SEM; \*\*\* p<0.001 (Unpaired t-test); (n = 15 cells, 4 slices, 3 mice for 3 dptm; n = 18 cells, 5 slices, 4 mice for 7 dptm; n = 18 cells, 5 slices, 4 mice for 14 dptm for each experimental group).



b

# Supplementary Fig. 4: ultrastructural localization of neurotrophins in astrocytic microdomains

(a) Schematic representation of cleaved BDNFpro domain.  $\alpha$ BDNFpro antibody recognizes the furin cleavage site of the prodomain. EM images depicting BDNFpro-gold particles (red arrowheads) in a limited fraction (230 nm radius) of the astrocyte surrounding the axon bouton. Scale bars: 200 nm.

(b) Schematic representation of the different neurotrophins isoforms recognized by  $\alpha$ mBDNF antibody. EM image depicting  $\alpha$ mBDNF-gold localization at astrocytic microdomains in sections from TBS- slices. Scale bar: 100 nm.

(c) Schematic representation of the different neurotrophins isoforms recognized by αproBDNF antibody. EM images depicting αproBDNF-gold localization at astrocytic microdomains in sections from TBS- slices. Scale bar: 100 nm.



\*\*\*

#### Supplementary Fig.5: rescues of LTP deficit in p75-flox mice

(a) Schematic representation of the experimental design. Step I, deletion of p75<sup>NTR</sup> in astrocytes from tamoxifen-treated p75-flox mice precludes proBDNF transfer from neurons to astrocyte following TBS. LV-GFP<sup>stop</sup> transduction in astrocytes results in loss of the GFP and expression of Tomato reporter. Graph shows LTP evoked in slices from p75-flox mice and control littermates treated with tamoxifen (-5 to 0) and injected with the appropriate lentivirus (12 dptm). \*\*\* p<0.001 (Unpaired t-test); (control littermates/LV-GFP<sup>stop</sup> 166,57 ± 3,78 %, p75-flox/LV-GFP<sup>stop</sup> 107,22 ± 7,16 % fEPSP 180 min from TBS; n = 7 slices, 5 mice for control littermates/LV-GFP<sup>stop</sup>; n = 9 slices, 5 mice for p75-flox/LV-GFP<sup>stop</sup>).

(b) Schematic representation of the experimental design. Step I, as in (a). Step II, LV-proBDNF<sup>stop</sup> transduction in astrocytes results in loss of the GFP and proBDNF expression. Graph shows LTP evoked in slices from p75-flox mice and control littermates as in (a). (control littermates/LV-GFP<sup>stop</sup> 153,49  $\pm$  2,22 %, p75-flox/LV-proBDNF<sup>stop</sup> 166,57  $\pm$  3,78 fEPSP 180 min from TBS; (n = 6 slices, 5 mice for control littermates/LV-GFP<sup>stop</sup>; n = 8 slices, 4 mice for p75-flox/LV-proBDNF<sup>stop</sup>).

(c) Schematic representation of the experimental design. Step I, as in (a). Step II, LV-proBDNF<sup>CRstop</sup> transduction in astrocytes results in loss of the GFP and expression of the cleavage-resistant proBDNF<sup>CR</sup>. Graph shows LTP evoked in slices from p75-flox mice and control littermates as in (a). \*\*\* p<0.001 (Unpaired t-test); (control littermates/LV-GFP<sup>stop</sup> 149,72 ± 5,93 %, p75-flox/LV- proBDNF<sup>CRstop</sup> 109, 19 ± 7,00 % fEPSP 180 min from TBS; n = 6 slices, 4 mice for control littermates/LV-GFP<sup>stop</sup>; n = 10 slices, 6 mice for p75-flox/LV-proBDNF<sup>CRstop</sup>).

(d) Schematic representation of the experimental design. Step I, as in (a). Step II, LV-BDNFpro<sup>stop</sup> transduction in astrocytes results in loss of the GFP and expression of BDNFpro. Graph shows LTP evoked in slices from p75-flox mice and control littermates as in (a). Data are presented as mean  $\pm$  SEM; (control littermates/LV-GFP<sup>stop</sup> 159,19  $\pm$  1,70 %, p75-flox/LV- BDNFpro<sup>stop</sup> 178,15  $\pm$  9,84 % fEPSP 180 min from TBS; n = 7 slices, 6 mice for control littermates/LV-GFP<sup>stop</sup>; n = 9 slices, 5 mice for p75-flox/LV-BDNFpro<sup>stop</sup>).

Data are presented as mean  $\pm$  SEM;



Stimulation intensity (uA)

β-Gal baseline





Paired-pulse interval (ms)

b

#### Supplementary Fig.6: transduction properties of lentiviral constructs

(a) Schematic overview of the lentiviral vectors. A CMV promoter drives GFP expression stopped with stop codon. Two loxP sites flank a gene cassette encoding GFP for Cre-recombination. Tomato is under control of the IRES2 site and followed by the WPRE element. A single blunt EcoRV site for cloning BDNFpro or TeTN is indicated. Cre-recombination in astrocytes results in loss of the GFP and expression of BDNFpro or TeTN.

(b) z-stack reconstruction shows cortical astrocytes labeled by GFAP in tamoxifen-induced mice) Cre-recombination ( $\beta$ -Gal+) results in selective expression of the virus reporter gene in astrocytes. Representative GFAP+/ $\beta$ -Gal+/Tomato+ (square 1) and GFAP+/ $\beta$ -Gal-/Tomato- (square 2) astrocytes are shown. Scale bars: 10 µm.

(c) Schematic overview of the experimental design. p75-flox mice were induced with tamoxifen for 5 days (-5 to 0) and injected with lentiviruses at 0 and 12 dptm. At 14 dptm cortical slices from both injection times were subjected to basal stimulation (baseline) and processed for immunodetection. z-stack reconstruction shows BDNFpro/GFAP colocalization in astrocytes from p75-flox mice injected with LV-BDNFpro<sup>stop</sup> at 0 and 12 dptm. Slices from tamoxifen-treated control littermates injected with LV-GFP<sup>stop</sup> (0 dptm) and stimulated with TBS are also shown. Insets show GFAP signal. Quantification of BDNFpro/GFAP colocalization signal using Mander's overlap is shown. (n = 10 cells, 4 slices, 3 mice for control littermates/LV-GFP<sup>stop</sup>/TBS; n = 14 cells, 4 slices, 4 mice for p75-flox/LV-BDNFpro<sup>stop</sup>/0 dptm/baseline; n = 12 cells, 4 slices, 4 mice for p75-flox/LV-BDNFpro<sup>stop</sup>/12 dptm/baseline). Scale bars: 10  $\mu$ m.

(d) Schematic diagram shows the experimental paradigm. Mice were induced with tamoxifen for 5 days (-5 to 0) and injected with LV-GFP<sup>stop</sup> or LV-BDNFpro<sup>stop</sup> (0 dptm) for field recording (14 dptm). Graph shows input\output curve (n=12 slices, 4 mice for control littermates/LV-GFP<sup>stop</sup>; n=14 slices, 4 mice for p75-flox/LV-BDNFpro<sup>stop</sup>).

(e) Schematic diagram shows the experimental paradigm as in (d). Graph shows paired-pulse facilitation with an interstimulus interval of 25, 50, 100, 150 and 200 ms. (n=12 slices, 4 mice for control littermates/LV-GFP<sup>stop</sup>; n=14 slices, 4 mice for p75-flox/LV-BDNFpro<sup>stop</sup>).

Data are presented as mean  $\pm$  SEM;



#### Supplementary Fig.7: exogenous neurotrophins rescue LTP deficit in p75-flox mice

(a) Schematic diagram shows the experimental paradigm. Tamoxifen was given for 5 consecutive days (-5 to 0) and recording performed at 14 dptm. Histogram depicts LTP evoked in slices from p75-flox mice and control littermates perfused (18 to 28 min) with vehicle or exogenous mBDNF (10 ng/ml) or proBDNF<sup>CR</sup> (20 ng/ml). \*\*\* p<0.001 (Unpaired t-test); (p75-flox/proBDNF<sup>CR</sup> 100,40  $\pm$  4,25 %, p75-flox/mBDNF 150,66  $\pm$  5,27 % and control littermates/vehicle 158,69  $\pm$  2,30 fEPSP 180 min from TBS; n=8 slices, 4 mice for p75-flox/proBDNF<sup>CR</sup>; n=9 slices, 5 mice for p75-flox/mBDNF; n=7 slices, 4 mice for control littermates/vehicle).

(b) Schematic diagram shows the experimental paradigm as in (a). Histogram depicts BDNFpro (10 ng/ml) treatment (18 to 28 min) in the absence of TBS-stimulation. (n=6 slices, 3 mice).

(c) Schematic diagram shows the experimental paradigm as in (a). Histogram depicts LTP evoked in slices from p75-flox mice and control littermates perfused with exogenous BDNFpro (10 ng/ml) or vehicle at different times (100 to 110 min; 170 to 180 min). \*\*\* p<0.001 (Unpaired t-test); (p75-flox/BDNFpro (100-110 min) 160,07  $\pm$  7,92 %, p75-flox/BDNFpro (170-180 min) 101,56  $\pm$  7,79 % and control littermates/vehicle 146,13  $\pm$  3,30 fEPSP 180 min from TBS; (n=6 slices, 3 mice for p75-flox/BDNFpro (100-110 min); n=7 slices, 4 mice for p75-flox/BDNFpro (170-180 min); n= 6 slices, 4 mice for control littermates/vehicle).

Data are presented as mean  $\pm$ SEM;



## Supplementary Fig.8: TrkB/pTrkB colocalization

Confocal images of TrkB, pTrkB and TrkB/pTrkB colocalization signals in baseline- and TBSslices from p75-flox mice injected with LV-GFP<sup>stop</sup> and LV-BDNFpro<sup>stop</sup>. Scale bars: 40 µm.